The 41st stock acquisition rights and the 42nd stock acquisition rights (allocated to Mr. Ryo Kubota) were issued by third-party allotment, and total payments amounted to 1,800,000 yen. The 41st rights include provisions for floor and ceiling exercise prices, price calculation by adjustment date, and treatment of shareholder record dates. The 42nd rights include full allocation and a full ratchet provision; payment total was 1,200,200,000 yen. Exercise periods are from 2026-11-10 to 2028-11-10 and from 2026-11-10 to 2031-11-10, respectively.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4596","jir_company_name":"Kubota Pharmaceutical Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4596-20261109-01.pdf","jir_short_summary":"The 41st stock acquisition rights and the 42nd stock acquisition rights (allocated to Mr. Ryo Kubota) were issued by third-party allotment, and total payments amounted to 1,800,000 yen. The 41st rights include provisions for floor and ceiling exercise prices, price calculation by adjustment date, and treatment of shareholder record dates. The 42nd rights include full allocation and a full ratchet provision; payment total was 1,200,200,000 yen. Exercise periods are from 2026-11-10 to 2028-11-10 and from 2026-11-10 to 2031-11-10, respectively.","jir_summary":"### Issuance of Stock Acquisition Rights and Completion of Payment\nKubota Pharmaceutical Holdings Co., Ltd. announced the completion of payment on 2026-11-09 for the issuance by third-party allotment of the 41st stock acquisition rights (with exercise price adjustment clause) and the 42nd stock acquisition rights. The 41st stock acquisition rights consist of 200,000 units with a total issuance amount of 1,600,000 yen; the number of potentially dilutive shares is 20,000,000 shares, the floor exercise price is 30 yen, and there is no ceiling. The 42nd stock acquisition rights consist of 200,000 units with a total issuance amount of 200,000 yen; the number of potentially dilutive shares is 20,000,000 shares, the exercise price is 60 yen, and they include a full ratchet provision. The total payment amounts are reported as 1,201,600,000 yen and 1,200,200,000 yen, respectively.\n\n### Exercise Periods and Special Provisions\nThe exercise period for the 41st stock acquisition rights is from 2026-11-10 to 2028-11-10, and for the 42nd stock acquisition rights from 2026-11-10 to 2031-11-10. The 41st rights include conditions for adjustment of the exercise price, with detailed adjustment rules for periods such as shareholder record dates. The 42nd rights may be partially adjusted pursuant to a purchase agreement concluded with Mr. Ryo Kubota, and include conditions such as the approval of the Audit and Supervisory Committee.","jir_financial_highlights":"Total issuance amount for the 41st stock acquisition rights: 1,600,000 yen (Unknown)\nTotal issuance amount for the 42nd stock acquisition rights: 200,000 yen (Unknown)\nTotal exercise price amount for the 41st stock acquisition rights: 1,200,000,000 yen (Unknown)\nAmount of funds to be raised from the 42nd stock acquisition rights: 1,200,200,000 yen (Unknown)\nIssuance date of the 41st stock acquisition rights: Unknown (Unknown)","jir_category":"","jir_hashtags":"#KubotaPharmaceuticalHoldings, #StockAcquisitionRights, #StockOptions, #CapitalPolicy","jir_key_figures":"Total issuance amount for the 41st stock acquisition rights: 1,600,000 yen\nTotal issuance amount for the 42nd stock acquisition rights: 200,000 yen\nTotal exercise price amount for the 41st stock acquisition rights: 1,200,000,000 yen\nNumber of potentially dilutive shares from the 41st stock acquisition rights: 20,000,000 shares\nNumber of potentially dilutive shares from the 42nd stock acquisition rights: 20,000,000 shares\nExercise period 41st: 2026\/11\/10\u301c2028\/11\/10\nExercise period 42nd: 2026\/11\/10\u301c2031\/11\/10","jir_meta_title":"Kubota Pharmaceutical Holdings Co., Ltd. Announces Completion of Payment for Third-Party Allotted Stock Acquisition Rights | November 9, 2026","jir_meta_description":"Kubota Pharmaceutical Holdings Co., Ltd. announced completion of payment for the 41st and 42nd stock acquisition rights allotted to third parties. Summary of key terms including issuance amounts, exercise prices, potentially dilutive shares, exercise periods, and adjustment provisions.","jir_og_title":"Kubota Pharmaceutical Holdings Co., Ltd. Announces Completion of Payment for Stock Acquisition Rights","jir_og_description":"Kubota Pharmaceutical Holdings Co., Ltd. announced the completion of payment for the 41st and 42nd stock acquisition rights. Review details on exercise price adjustment clauses, exercise periods, and potentially dilutive share counts.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59981,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-145545","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n